KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability (2016 - 2019)

Arbutus Biopharma (ABUS) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $12.7 million as the latest value for Q2 2019.

  • Quarterly Non-Current Deferred Tax Liability fell 25.27% to $12.7 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $12.7 million through Jun 2019, down 25.27% year-over-year, with the annual reading at $12.7 million for FY2018, 25.27% down from the prior year.
  • Non-Current Deferred Tax Liability hit $12.7 million in Q2 2019 for Arbutus Biopharma, roughly flat from $12.7 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $156.0 million in Q2 2015 to a low of $12.7 million in Q3 2018.
  • Historically, Non-Current Deferred Tax Liability has averaged $60.0 million across 5 years, with a median of $41.3 million in 2016.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: plummeted 71.8% in 2016 and later fell 25.27% in 2018.
  • Year by year, Non-Current Deferred Tax Liability stood at $146.3 million in 2015, then tumbled by 71.8% to $41.3 million in 2016, then plummeted by 58.94% to $16.9 million in 2017, then dropped by 25.27% to $12.7 million in 2018, then changed by 0.0% to $12.7 million in 2019.
  • Business Quant data shows Non-Current Deferred Tax Liability for ABUS at $12.7 million in Q2 2019, $12.7 million in Q1 2019, and $12.7 million in Q4 2018.